CA2115675A1 - Method for lowering blood lipid levels - Google Patents

Method for lowering blood lipid levels

Info

Publication number
CA2115675A1
CA2115675A1 CA002115675A CA2115675A CA2115675A1 CA 2115675 A1 CA2115675 A1 CA 2115675A1 CA 002115675 A CA002115675 A CA 002115675A CA 2115675 A CA2115675 A CA 2115675A CA 2115675 A1 CA2115675 A1 CA 2115675A1
Authority
CA
Canada
Prior art keywords
lipid
mimetic
pro
drug
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002115675A
Other languages
English (en)
French (fr)
Inventor
Georges H. VAN DEN BERGHE
Harry E. Gruber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2115675A1 publication Critical patent/CA2115675A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002115675A 1991-08-23 1992-08-14 Method for lowering blood lipid levels Abandoned CA2115675A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74894491A 1991-08-23 1991-08-23
US07/748,944 1991-08-23
US92975292A 1992-08-12 1992-08-12
US07/929,752 1992-08-12

Publications (1)

Publication Number Publication Date
CA2115675A1 true CA2115675A1 (en) 1993-03-04

Family

ID=27115023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002115675A Abandoned CA2115675A1 (en) 1991-08-23 1992-08-14 Method for lowering blood lipid levels

Country Status (7)

Country Link
EP (1) EP0599987A4 (no)
AU (1) AU2486192A (no)
CA (1) CA2115675A1 (no)
IL (1) IL102895A0 (no)
MX (1) MX9204880A (no)
NO (1) NO940580L (no)
WO (1) WO1993003734A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002943A1 (en) * 2001-10-31 2005-01-06 Oberdan Leo Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ES2192495B1 (es) 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
WO2015042821A1 (zh) * 2013-09-26 2015-04-02 华安医学股份有限公司 活化ampk的化合物及其使用
CA3107170A1 (en) 2018-08-06 2020-03-12 Skylark Bioscience Llc Amp-activated protein kinase activating compounds and uses thereof
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2026040C3 (de) * 1970-05-27 1975-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Imidazolribosylcyclophosphate
US3919192A (en) * 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells

Also Published As

Publication number Publication date
EP0599987A4 (en) 1995-02-01
EP0599987A1 (en) 1994-06-08
AU2486192A (en) 1993-03-16
IL102895A0 (en) 1993-01-31
NO940580L (no) 1994-04-25
WO1993003734A1 (en) 1993-03-04
MX9204880A (es) 1993-04-01
NO940580D0 (no) 1994-02-21

Similar Documents

Publication Publication Date Title
Brown et al. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
Spector et al. Role of acylcoenzyme A: cholesterol o-acyltransferase in cholesterol metabolism.
Kowluru et al. Hyperactivation of protein phosphatase 2A in models of glucolipotoxicity and diabetes: potential mechanisms and functional consequences
Cardinali et al. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications
Kamanna et al. Mechanism of action of niacin on lipoprotein metabolism
Randle et al. Mechanisms modifying glucose oxidation in diabetes mellitus
Jungas et al. Studies on the metabolism of adipose tissue. XII. The effects of insulin and epinephrine on free fatty acid and glycerol production in the presence and absence of glucose
Saxena et al. Transport of lipoprotein lipase across endothelial cells.
US20050209243A1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
EP1746982A2 (en) Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis and cardiovascular diseases
Lin et al. KMUP‐1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K+ channels
Henzel et al. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid
CA2115675A1 (en) Method for lowering blood lipid levels
WO2005009433A1 (en) Use of 3,5 diiodothyronine as regulators of lipid metabolism
US6979687B1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
EP1765357A2 (en) Use of atp analogues for treatment of cardiovascular diseases
O’Keefe et al. Development of whole-body and skeletal muscle insulin resistance after one day of hindlimb suspension
Tanaka et al. Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells
West et al. L-Arginine prevents metabolic effects of high glucose in diabetic mice
EP0393180B1 (en) 26-aminocholesterol and derivatives and analogs thereof in the regulation of cholesterol accumulation in body tissue
Frigerio et al. The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate
Gao et al. NPRA-mediated suppression of AngII-induced ROS production contribute to the antiproliferative effects of B-type natriuretic peptide in VSMC
O'Brien et al. Overview: ACAT Inhibitors: A Potential New Approach to the Treatment of Hypercholesterolaemia and Atherosclerosis
Bhatnagar et al. Regulation of vascular smooth muscle cell growth by aldose reductase
Hajjar Prostaglandins modulate arterial cholesteryl ester metabolism

Legal Events

Date Code Title Description
FZDE Discontinued